Virpax Pharmaceuticals IncNASDAQ:VRPXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE1.3800
- TODAY'S CHANGE (%)-0.1300 (-8.6093%)
- Bid / Lots1.3800/ 58
- Ask / Lots1.4100/ 10
- Open / Previous Close1.5500 / 1.5100
- Day Range
- 52 Week Range
- Volume590,827
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VRPX |
|---|---|---|
| 09:32 ET | 1134 | 1.55 |
| 09:34 ET | 645 | 1.545 |
| 09:36 ET | 17939 | 1.5 |
| 09:38 ET | 2422 | 1.48 |
| 09:39 ET | 787 | 1.4988 |
| 09:41 ET | 120 | 1.4987 |
| 09:43 ET | 14362 | 1.48 |
| 09:45 ET | 135 | 1.4998 |
| 09:48 ET | 5122 | 1.5051 |
| 09:50 ET | 101 | 1.5001 |
| 09:52 ET | 302 | 1.49 |
| 09:54 ET | 4184 | 1.4808 |
| 09:56 ET | 3125 | 1.4799 |
| 09:57 ET | 1450 | 1.4691 |
| 09:59 ET | 14700 | 1.4599 |
| 10:01 ET | 4780 | 1.47 |
| 10:03 ET | 393 | 1.46 |
| 10:06 ET | 10691 | 1.4576 |
| 10:08 ET | 2100 | 1.45 |
| 10:10 ET | 4681 | 1.46 |
| 10:12 ET | 969 | 1.46 |
| 10:14 ET | 11145 | 1.435 |
| 10:15 ET | 7747 | 1.44 |
| 10:17 ET | 175 | 1.445 |
| 10:19 ET | 2300 | 1.4499 |
| 10:21 ET | 2978 | 1.44 |
| 10:24 ET | 3302 | 1.45 |
| 10:26 ET | 536 | 1.46 |
| 10:28 ET | 1500 | 1.47 |
| 10:30 ET | 5021 | 1.48 |
| 10:32 ET | 470 | 1.4895 |
| 10:33 ET | 3016 | 1.4699 |
| 10:35 ET | 6626 | 1.4601 |
| 10:37 ET | 250 | 1.4699 |
| 10:39 ET | 597 | 1.4699 |
| 10:42 ET | 6856 | 1.4601 |
| 10:44 ET | 4166 | 1.4613 |
| 10:46 ET | 7974 | 1.48 |
| 10:48 ET | 825 | 1.48 |
| 10:50 ET | 4500 | 1.4799 |
| 10:55 ET | 338 | 1.47 |
| 10:57 ET | 1923 | 1.5 |
| 11:00 ET | 600 | 1.51 |
| 11:04 ET | 139 | 1.52 |
| 11:06 ET | 11825 | 1.514 |
| 11:08 ET | 1158 | 1.5095 |
| 11:09 ET | 200 | 1.51 |
| 11:13 ET | 7913 | 1.51 |
| 11:15 ET | 500 | 1.51 |
| 11:22 ET | 350 | 1.514 |
| 11:26 ET | 4500 | 1.5 |
| 11:29 ET | 2021 | 1.5199 |
| 11:31 ET | 9095 | 1.5001 |
| 11:33 ET | 298 | 1.5 |
| 11:36 ET | 2011 | 1.505 |
| 11:40 ET | 5191 | 1.5 |
| 11:42 ET | 1550 | 1.49 |
| 11:44 ET | 1575 | 1.48 |
| 11:45 ET | 1191 | 1.48 |
| 11:47 ET | 200 | 1.49 |
| 11:49 ET | 5475 | 1.4807 |
| 11:54 ET | 5000 | 1.4801 |
| 11:56 ET | 9702 | 1.4802 |
| 12:00 ET | 125 | 1.495 |
| 12:05 ET | 300 | 1.49 |
| 12:07 ET | 500 | 1.4831 |
| 12:09 ET | 7000 | 1.4999 |
| 12:12 ET | 780 | 1.49 |
| 12:16 ET | 9377 | 1.48 |
| 12:18 ET | 7050 | 1.49 |
| 12:25 ET | 1300 | 1.5 |
| 12:32 ET | 1095 | 1.5 |
| 12:34 ET | 1400 | 1.5 |
| 12:43 ET | 3833 | 1.49 |
| 12:45 ET | 4346 | 1.485 |
| 12:59 ET | 220 | 1.4807 |
| 01:01 ET | 1100 | 1.4801 |
| 01:03 ET | 4600 | 1.4799 |
| 01:10 ET | 1580 | 1.49 |
| 01:19 ET | 6312 | 1.48 |
| 01:21 ET | 510 | 1.48 |
| 01:28 ET | 3265 | 1.47 |
| 01:30 ET | 12840 | 1.46 |
| 01:32 ET | 1520 | 1.441 |
| 01:33 ET | 3054 | 1.4501 |
| 01:35 ET | 600 | 1.46 |
| 01:37 ET | 1568 | 1.45 |
| 01:42 ET | 478 | 1.45 |
| 01:55 ET | 100 | 1.45 |
| 02:06 ET | 100 | 1.46 |
| 02:08 ET | 9065 | 1.46 |
| 02:09 ET | 1781 | 1.4501 |
| 02:13 ET | 156 | 1.441 |
| 02:15 ET | 485 | 1.4596 |
| 02:18 ET | 102 | 1.4597 |
| 02:22 ET | 14903 | 1.43 |
| 02:24 ET | 13600 | 1.44 |
| 02:26 ET | 582 | 1.44 |
| 02:27 ET | 1500 | 1.45 |
| 02:29 ET | 2540 | 1.4599 |
| 02:42 ET | 1100 | 1.47 |
| 02:44 ET | 1103 | 1.48 |
| 03:09 ET | 579 | 1.454 |
| 03:12 ET | 600 | 1.4505 |
| 03:14 ET | 450 | 1.451 |
| 03:16 ET | 675 | 1.465 |
| 03:18 ET | 1125 | 1.465 |
| 03:20 ET | 100 | 1.46 |
| 03:23 ET | 109 | 1.46 |
| 03:25 ET | 3100 | 1.46 |
| 03:27 ET | 1636 | 1.4601 |
| 03:32 ET | 110 | 1.46 |
| 03:38 ET | 37935 | 1.4 |
| 03:39 ET | 3684 | 1.43 |
| 03:41 ET | 77512 | 1.38 |
| 03:43 ET | 1150 | 1.3899 |
| 03:45 ET | 5777 | 1.37 |
| 03:48 ET | 800 | 1.37 |
| 03:50 ET | 4795 | 1.405 |
| 03:52 ET | 9953 | 1.3999 |
| 03:54 ET | 10518 | 1.396 |
| 03:56 ET | 675 | 1.405 |
| 03:57 ET | 1200 | 1.408 |
| 03:59 ET | 5155 | 1.38 |
Jul 24, 2024
Virpax Regains Compliance with Nasdaq Minimum Bid Price, from 7:30AM ET on Wednesday Jul 24, 2024 by Dow Jones
7:30AM ET on Wednesday Jul 24, 2024 by Dow Jones
Jul 19, 2024
DJ Virpax Pharmaceuticals Raised to Buy From Hold by Maxim Group, from 9:31AM ET on Friday Jul 19, 2024 by Dow Jones
9:31AM ET on Friday Jul 19, 2024 by Dow Jones
Jul 10, 2024
Virpax Announces Positive Results of Swine Model Pilot Study for Probudur(TM), from 7:30AM ET on Wednesday Jul 10, 2024 by Dow Jones
7:30AM ET on Wednesday Jul 10, 2024 by Dow Jones
Jul 8, 2024
*DJ Virpax Pharmaceuticals Secures $2.5M Secured Loan From Institutional Investor >VRPX, from 7:31AM ET on Monday Jul 08, 2024 by Dow Jones
7:31AM ET on Monday Jul 08, 2024 by Dow JonesVirpax Pharmaceuticals Secures $2.5 Million Loan Financing and an Agreement with an Institutional Investor to Negotiate Additional Funding, from 7:30AM ET on Monday Jul 08, 2024 by Dow Jones
7:30AM ET on Monday Jul 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Virpax Pharmaceuticals Inc | 7.3M | -0.1x | --- |
Chromocell Therapeutics Corp | 7.4M | -0.9x | --- |
Vaxxinity Inc | 7.6M | -0.1x | --- |
GlucoTrack Inc | 7.8M | -0.7x | --- |
Galera Therapeutics Inc | 6.8M | -0.1x | --- |
National Graphite Corp | 7.9M | -2.4x | --- |
Company Information
Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on developing novel and proprietary drug delivery systems across various pain indication. Its drug-delivery systems and drug-releasing technologies being developed are focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system (CNS) disorders to enhance patients’ quality of life. Its portfolio consists of multiple preclinical stage product candidates: Epoladerm, Probudur, Envelta, AnQlar and NobrXiol. Probudur is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. The NobrXiol is being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy.
Contact Information
- Headquarters
- 1055 Westlakes Drive, Suite 300BERWYN, PA, United States 19312
- Phone
- 610-727-4597
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Eric Floyd
- Chief Executive Officer, Director
- Gerald Bruce
- Chief Financial Officer, Corporate Secretary
- Vinay Shah
- Chief Scientific Officer
- Sheila Mathias
- Independent Director
- Michael Dubin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $7.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 4.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.73 |
EPS | $-14.42 |
Book Value | $1.65 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
